medRxiv
Amyloid-PET pipeline choice influences classification of preclinical Alzheimers disease
Preprint: cohort study of 433 peopleBiomarkers
Declared ties to: Biogen, Merck & Co., Eisai and 19 more
Abstract
BACKGROUNDQuantitative amyloid-beta (A{beta})-PET is increasingly used in AD prevention trials. Although the Centiloid (CL) framework provides a common scale, variability persists across processing pipelines, including differences in template/native space, partial volume correction (PVC), and reference region.
The paper
University of Wisconsin–Madison; UK Dementia Research Institute
medRxiv, 19 Aug 2026, CC BY, Preprint, not peer-reviewed
